Feeley Kevin 4

What Happened

• Kevin Feeley, Chief Financial Officer of GeneDx Holdings Corp. (WGS), had 2,462 restricted stock units (RSUs) convert/settle into 2,462 shares on June 9, 2026 (acquired at $0 per share). On the same day he sold 1,266 of those shares in an open-market "sell-to-cover" transaction at $53.77 per share, generating proceeds of $68,073. The filing also records the RSU/derivative conversion related to that settlement.

Key Details

• Transaction date: June 9, 2026. Sale price: $53.77 per share; sale proceeds: $68,073 for 1,266 shares.
• RSU settlement: 2,462 shares were issued upon conversion/vesting at $0 (no cash consideration).
• Shares owned after transaction: 36,486 shares of Class A common stock beneficially owned, plus RSUs representing rights to up to 89,240 additional shares and options to purchase up to 25,906 shares (per footnote F3).
• Notable footnotes: F2 — the sale was a sell-to-cover to satisfy tax withholding and was not a discretionary sale; F1/F4 — RSUs represent contingent rights to shares, vesting 6.25% quarterly with no expiration for these RSUs.
• Filing timeliness: Form 4 was filed June 11, 2026 for a June 9 transaction (filed within the typical two-business-day window).

Context

• This was a routine sell-to-cover following RSU settlement (cashless/automatic withholding), not a straightforward market-directed sell for investment reasons. Such transactions are common when RSUs vest and are used solely to satisfy tax obligations.